A number of research firms have changed their ratings and price targets for Versigent (NYSE: VGNT):
- 7/13/2026 – Versigent had its price target raised by Royal Bank Of Canada from $34.00 to $41.00. They now have a “sector perform” rating on the stock.
- 7/9/2026 – Versigent had its price target lowered by UBS Group AG from $58.00 to $55.00. They now have a “buy” rating on the stock.
- 7/7/2026 – Versigent was upgraded by Deutsche Bank Aktiengesellschaft from “hold” to “buy”. They now have a $50.00 price target on the stock.
- 7/2/2026 – Versigent was upgraded by Zacks Research from “hold” to “strong-buy”.
- 6/25/2026 – Versigent had its price target raised by Wells Fargo & Company from $42.00 to $48.00. They now have an “overweight” rating on the stock.
- 6/5/2026 – Versigent had its price target raised by UBS Group AG from $49.00 to $58.00. They now have a “buy” rating on the stock.
- 5/18/2026 – Versigent had its “outperform” rating reaffirmed by Evercore Inc. They now have a $60.00 price target on the stock.
Featured Stories
- Five stocks we like better than Versigent
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.
